Novartis AG (ADR) news

   Watch this stock
Showing stories 1 - 10 of about 164   

Articles published

NVS 81.48 -0.55 (-0.67%)
price chart
Novartis AG (ADR) (NVS) Multiple Sclerosis Molecule: Ray of Hope
Novartis AG (ADR) (NYSE:NVS) investigational molecule for the treatment and management of multiple sclerosis has shown remarkable reduction in the disease progression up to 21%.
Novartis AG (ADR) 17% Potential Upside Now Implied by Chardan Capital Markets
Novartis AG (ADR) with TICKER NYSE:NVS has had its stock rating noted as 'Initiated' with the recommendation being set at 'BUY' yesterday by analysts at Chardan Capital Markets.
Novartis Ag (NYSE:NVS) Is A Stock Chardan Capital Is Interested In  Post News
Novartis AG (ADR) (NYSE:NVS) Says A Picture Is Worth A Thousand Words
How do you mix medicine and photography? That's what Novartis AG (ADR) (NYSE:NVS) is doing and it feels nothing strange about it.
Here's What's Important With The Novartis AG (ADR) (NVS) MS Data  Insider Monkey (blog)
Novartis AG (NYSE:NVS) Fights for Survival after Patent Expiration  TCC
Novartis AG (ADR) (NYSE:NVS): Reviewing Earnings Estimates
Novartis AG (ADR) (NYSE:NVS) soared 0.51% or +0.42 points during previous trade after opening at the price of $81.92, a total of 1.58M shares exchanged hands compared with its average trading volume of 1.71M shares.
Novartis AG (ADR) 2Q Earnings: Here's What To Expect?  Bidness ETC
Novartis (NVS) Beats Earnings & Sales in Q2  Nasdaq
Novartis AG (ADR) (NYSE:NVS) To Pay $25 Million Over Bribery Allegations
Last year GlaxoSmithKline plc (ADR) (NYSE:GSK) posted a 17% drop in sales as a state-led campaign on drug prices affected returns.
Will Novartis AG (ADR) (NVS) Clinch Biosimilar Market by 2020?
Novartis AG's (ADR)(NYSE:NVS) biosimilar and generic division, Sandoz is working for the development of novel biosimilars versions of the blockbuster drugs to patch up the revenue loss of its blockbuster drugs' patents.
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) shares tick higher 2.23% as ear ...  Benchmark Monitor
Amgen, Inc. (AMGN) and Novartis AG (ADR) (NVS) Erenumab: New Hope for Migraine ...
Amgen, Inc. (NASDAQ:AMGN) has announced that erenumab clinical results for the management and treatment of chronic migraine headaches have met the primary endpoints.
How Many Heart Failure Deaths Can Novartis AG (ADR) (NYSE:NVS) Entresto Reduce?
A fresh analysis of Novartis AG (ADR) (NYSE:NVS) drug Entresto has shown that it can significantly reduce heart failure deaths.
Will Novartis AG (ADR) (NVS) be Forbidden in Korea after Bribe Charges?
Novartis AG (ADR) (NYSE:NVS) is hit by bad news of involvement of its six senior officials under the charges of corruption.
Novartis AG (NYSE:NVS) To Spend $100 Million On Expansion Of French mAb Plant  Market Exclusive
The Biosimilar of Amgen's Enbrel, by Novartis AG (ADR) (NYSE:NVS), has been ...
In a latest development, the Food and Drug Administration (FDA) has announced the approval of Novartis AG's (NYSE:NVS) Erelzi, which is a biosimilar version of Amgen's blockbuster drug Enbrel.
Novartis AG (ADR) Enbrel Biosimilar Approved: What's Next for Amgen?  Smаrt Stоck Nеws
Amgen, Inc: How Damaging Will Be Novartis' Enbrel Copy  Bidness ETC